Combination effect of bis(3-methylsulfonyloxypropyl)amide and 6-mercaptopurine on AH-60C and AH-109A.
Survival period of rats bearing ascites hepatoma, AH-60C, which was less sensitive to bis (3-methylsulfonyloxypropyl)amine (864-T) and 6-mercaptopurine each alone, was prolonged by the combined treatment with these two agents. Two or 3 rats in groups of 12 animals each survived over 60 days by this combined therapy beginning from day 0. In AH-109A, which was insensitive to 6-mercaptopurine, the group treated with this combination did not survive longer than that with 864-T alone.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D007274:Injections, Intraperitoneal; D008113:Liver Neoplasms; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000627:therapeutic use; D008698:Mesylates / Q000008:administration & dosage* / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008698:Mesylates; D009588:Nitrogen Mustard Compounds; D014105:Tosyl Compounds; D015122:Mercaptopurine